News Development and Performance of Pharmacodynamic Assays to Demonstrate Proof-of-Mechanism for IRAK4 Degraders in a Phase1 Study 10/26/22 Read more The Phase 1 Healthy Volunteer Clinical Trial of KT-474 10/26/22 Read more Utilizing degraders to Modulate B & T Cell Targets for Autoimmune Diseases 7/28/22 Read more Discovery and characterization of IRAKIMiDs: degraders targeting both IRAK4 and IMiD substrates for oncology indications 6/7/22 Read more Discovery and targeted mass spectrometry-based proteomics: Enabling technologies advancing IRAK4 protein degrader along the drug discovery pipeline into the clinic 6/6/22 Read more Kinetics of IRAK4 Degradation and Impact on Functional Response in Circulating Immune Cells and Skin Cell Subsets 5/17/22 Read more Selective IRAK4 Degradation, Not Kinase Inhibition, Blocks TLR-activated NF-kB and p38 Signaling Leading to broad Cytokine Inhibition 5/3/22 Read more European Protein Degradation Congress, September 21st-23rd, 2021 9/21/21 Read more The First Proof-of-Mechanism in a Randomized, Placebo-controlled Study in Targeted Protein Degradation 7/6/21 Read more 16th Annual International Conference on Malignant Lymphoma (ICML) Virtual Meeting, June 18 – 22, 2021 6/20/21 Read more
